Nicollet Mall

Apria Completes Secondary Offering of Common Stock

Retrieved on: 
Monday, November 15, 2021
Securities Exchange Act of 1934, Goldman Sachs, TD, TD Securities, Pressure, Prospectus, Security (finance), Nicollet Mall, BofA Securities, Joint Commission, Telephone, Securities Act of 1933, Attention, Blackstone, UBS, Forward-looking statement, Capital market, LLC, Sale, Citigroup, U.S. Securities and Exchange Commission, Stern, Company, Disclosure, Broadridge Financial Solutions, GLOBE, SEC, Review, Patient, Obstructive sleep apnea

INDIANAPOLIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today the completion of a secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share, resulting in gross proceeds of $141.75 million.

Key Points: 
  • INDIANAPOLIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today the completion of a secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share, resulting in gross proceeds of $141.75 million.
  • Apria did not offer any shares of its common stock and did not receive any net proceeds from the sale of common stock by the selling stockholder.
  • BofA Securities, UBS Investment Bank and Piper Sandler acted as joint book-running managers for the offering.
  • These statements include any statements regarding the proposed offering of Apria common stock and other non-historical statements.

Apria Announces Pricing of Secondary Offering of Common Stock

Retrieved on: 
Thursday, November 11, 2021
Securities Exchange Act of 1934, Goldman Sachs, TD, TD Securities, Pressure, Prospectus, Security (finance), Nicollet Mall, BofA Securities, Joint Commission, Telephone, Securities Act of 1933, Attention, Blackstone, UBS, Forward-looking statement, Capital market, LLC, Sale, Citigroup, U.S. Securities and Exchange Commission, Stern, Company, Disclosure, Broadridge Financial Solutions, GLOBE, SEC, Review, Patient, Obstructive sleep apnea

INDIANAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today the pricing of a previously announced secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share.

Key Points: 
  • INDIANAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today the pricing of a previously announced secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share.
  • The selling stockholder has also granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock.
  • Apria is not offering any shares of its common stock and will not receive any net proceeds from the sale of common stock by the selling stockholder.
  • These statements include any statements regarding the proposed offering of Apria common stock and other non-historical statements.

MDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States

Retrieved on: 
Thursday, November 4, 2021
USD, Oppenheimer, Financial Services and Markets Act 2000, Minnesota, European Central Bank, Central bank, CA, KBC, Person, Financial services, Nicollet Mall, Article 49 of the French Constitution, American depositary receipt, Broad Street, EUR, Finance, Article, U.S. Securities and Exchange Commission, Exercise, ADSS, SEC filing, MTV Europe Music Award for Best Belgian Act, United Kingdom, Company, Nasdaq, ADS, Offering, Order, Attention, Article 19, Prospectus, Sale, European Economic Area, Urban economics, Form, Security (finance), Cryptocurrency

The closing of the Offering is expected to occur on November 8, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the Offering is expected to occur on November 8, 2021, subject to the satisfaction of customary closing conditions.
  • The ADSs are expected to begin trading on the NASDAQ Capital Market on November 4, 2021 under the symbol MDXH.
  • The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
  • NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA ("MDxHealth").

Arhaus Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, November 4, 2021
Retail, Home Goods, Professional Services, Finance, BofA Securities, 2nd Floor (Nina song), Barclays, Security (finance), Nicollet Mall, U.S. Securities and Exchange Commission, Varick Street, Telephone, Guggenheim Partners, Morgan Stanley, Jefferies, Nasdaq, Madison Avenue, Company, Jefferies Group, Prospectus, Attention, Omnichannel, Sale, Baird, Form

Arhaus, Inc. (Arhaus), a rapidly growing lifestyle brand and omni-channel retailer of premium home furnishings, today announced the pricing of its initial public offering of 12,903,226 shares of its Class A common stock at a price of $13.00 per share.

Key Points: 
  • Arhaus, Inc. (Arhaus), a rapidly growing lifestyle brand and omni-channel retailer of premium home furnishings, today announced the pricing of its initial public offering of 12,903,226 shares of its Class A common stock at a price of $13.00 per share.
  • In addition, the underwriters will have a 30-day option to purchase from the Company up to an additional 1,935,484 shares of its Class A common stock at the initial public offering price, less any underwriting discounts and commissions.
  • The offering is expected to close on November 8, 2021, subject to customary closing conditions.
  • BofA Securities and Jefferies LLC are acting as joint lead book-running managers and as representatives for the proposed offering.

Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, November 2, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, 2nd Floor (Nina song), Minnesota, Broadridge Financial Solutions, ATR, Nicollet Mall, View, Varick Street, Telephone, Cowen Inc., U.S. Securities and Exchange Commission, SEC, Reparations (transitional justice), Exercise, CRISPR, Morgan Stanley, LLC, Company, Goldman Sachs, PKMYT1, Attention, Nasdaq, Prospectus, Therapy, Genome, Sale, DNA, Security (finance), Pharmaceutical industry

The total gross proceeds for the offering were approximately $101.2 million, before deducting underwriting commissions and offering expenses payable by Repare.

Key Points: 
  • The total gross proceeds for the offering were approximately $101.2 million, before deducting underwriting commissions and offering expenses payable by Repare.
  • Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler acted as joint book-running managers for the offering.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006348/en/

AirSculpt Technologies, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, October 29, 2021
2nd Floor (Nina song), State Street, SVB Leerink, Security (finance), Bangladesh Securities and Exchange Commission, Nicollet Mall, Patient, Varick Street, SEC, Morgan Stanley, Company, MIAMI, Attention, Prospectus, GLOBE, Sale, Nasdaq, Financial adviser

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock from certain selling stockholders at the initial public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock from certain selling stockholders at the initial public offering price, less underwriting discounts and commissions.
  • Morgan Stanley, Piper Sandler & Co. and SVB Leerink LLC are acting as lead book-running managers for the proposed offering.
  • A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on October 28, 2021.
  • AirSculpt Technologies is an experienced, fast-growing national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture.

Sonendo, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, October 29, 2021
Biotechnology, Health, Dental, Medical Devices, Method, BofA Securities, 3rd Floor, Practice management, Workflow, Conditional sentence, Software, Nicollet Mall, Root canal treatment, U.S. Securities and Exchange Commission, Stifel, Communication, CBCT, New, Forward-looking statement, Company, Goldman Sachs, Economics, Tooth decay, Prospectus, Risk, Sale, Form, Security (finance)

Sonendo, Inc., a leading dental technology company and developer of the GentleWave System, today announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, for total gross proceeds of $93.6 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • Sonendo, Inc., a leading dental technology company and developer of the GentleWave System, today announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, for total gross proceeds of $93.6 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • The offering is expected to close on November 2, 2021, subject to the satisfaction of customary closing conditions.
  • In addition, Sonendo has granted the underwriters a 30-day option to purchase up to an additional 1,170,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
  • Certain statements contained in this press release constitute forward-looking statements, including with respect to the proposed initial public offering.

MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States

Retrieved on: 
Thursday, October 28, 2021
Oppenheimer, Financial Services and Markets Act 2000, Minnesota, CA, KBC, Person, Financial services, Nicollet Mall, Article 49 of the French Constitution, American depositary receipt, Broad Street, Finance, Article, U.S. Securities and Exchange Commission, Nasdaq, ADSS, SEC filing, Company, MTV Europe Music Award for Best Belgian Act, United Kingdom, ADS, Offering, Order, Attention, Exchange, Article 19, Prospectus, Sale, European Economic Area, Urban economics, Form, Security (finance)

An application has been made to list the ADSs on the Nasdaq Capital Market under the same symbol.

Key Points: 
  • An application has been made to list the ADSs on the Nasdaq Capital Market under the same symbol.
  • The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
  • NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA ("MDxHealth").
  • No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium.

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Health, Oncology, Clinical Trials, 2nd Floor (Nina song), Minnesota, Broadridge Financial Solutions, Failure, ATR, Nicollet Mall, Private Securities Litigation Reform Act, Varick Street, Telephone, Cowen Inc., U.S. Securities and Exchange Commission, SEC, CRISPR, Morgan Stanley, LLC, Company, Goldman Sachs, PKMYT1, Attention, Nasdaq, Prospectus, Therapy, Risk, Genome, Sale, DNA, Security (finance)

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare.

Key Points: 
  • Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare.
  • All of the common shares are being offered by Repare.
  • In addition, Repare has granted the underwriters a 30-day option to purchase up to an additional 600,000 of its common shares at the public offering price, less underwriting commissions.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics Announces Proposed Public Offering of Common Shares

Retrieved on: 
Wednesday, October 27, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, 2nd Floor (Nina song), Minnesota, Broadridge Financial Solutions, Failure, ATR, Nicollet Mall, Private Securities Litigation Reform Act, Varick Street, Telephone, Cowen Inc., U.S. Securities and Exchange Commission, SEC, CRISPR, Morgan Stanley, LLC, Company, Goldman Sachs, PKMYT1, Attention, Nasdaq, Prospectus, Therapy, Risk, Genome, Sale, DNA, Security (finance)

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares.

Key Points: 
  • Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares.
  • All common shares to be sold in the proposed offering will be sold by Repare.
  • Repare also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares at the public offering price, less underwriting commissions.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.